Dysfunction of the neurovascular unit in brain aging

Shu Liu; Xu Yang; Fei Chen; Zhiyou Cai

doi:10.7555/JBR.36.20220105

Volume 37 Issue 3

May 2023

Turn off MathJax

Article Contents

Abstract

References

The Journal of Biomedical Research > 2023 > 37(3): 153-165. > DOI: 10.7555/JBR.36.20220105

Shu Liu, Xu Yang, Fei Chen, Zhiyou Cai. Dysfunction of the neurovascular unit in brain aging[J]. The Journal of Biomedical Research, 2023, 37(3): 153-165. DOI: 10.7555/JBR.36.20220105

Citation:

Shu Liu, Xu Yang, Fei Chen, Zhiyou Cai. Dysfunction of the neurovascular unit in brain aging[J]. The Journal of Biomedical Research, 2023, 37(3): 153-165. DOI: 10.7555/JBR.36.20220105

Citation:

Shu Liu, Xu Yang, Fei Chen, Zhiyou Cai. Dysfunction of the neurovascular unit in brain aging[J]. The Journal of Biomedical Research, 2023, 37(3): 153-165. DOI: 10.7555/JBR.36.20220105

PDF (12409 KB)

Dysfunction of the neurovascular unit in brain aging

Shu Liu^{1, 2, 3, 4, 5},
Xu Yang^{4, 5},
Fei Chen^{1, 2},
Zhiyou Cai^{1, 2, 3, 4, 5, ,}

1.
Chongqing Medical University, Chongqing 400042, China
2.
Chongqing Institute Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing 400714, China
3.
Chongqing School, University of Chinese Academy of Sciences, Chongqing 400714, China
4.
Department of Neurology, Chongqing General Hospital, Chongqing 400013, China
5.
Chongqing Key Laboratory of Neurodegenerative Diseases, Chongqing 400013, China

More Information

Corresponding author:
Zhiyou Cai, Department of Neurology, Chongqing General Hospital, No. 312 Zhongshan First Road, Yuzhong District, Chongqing 400013, China. Tel/Fax: +86-23-63515796/+86-23-63515796, E-mail: caizhiyou@ucas.ac.cn
Received Date: June 06, 2022
Revised Date: September 09, 2022
Accepted Date: September 21, 2022
Available Online: April 14, 2023

Graphical Abstract

Abstract

Abstract

An emerging concept termed the neurovascular unit (NVU) underlines neurovascular coupling. It has been reported that NVU impairment can result in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Aging is a complex and irreversible process caused by programmed and damage-related factors. Loss of biological functions and increased susceptibility to additional neurodegenerative diseases are major characteristics of aging. In this review, we describe the basics of the NVU and discuss the effect of aging on NVU basics. Furthermore, we summarize the mechanisms that increase NVU susceptibility to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Finally, we discuss new treatments for neurodegenerative diseases and methods of maintaining an intact NVU that may delay or diminish aging.
- aging,
- neurovascular unit,
- Alzheimer's disease,
- Parkinson's disease

FullText(HTML)

CLC number: R741, Document code: A

The authors reported no conflict of interests.

References (107)

References

[1]	López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging[J]. Cell, 2013, 153(6): 1194–1217. doi: 10.1016/j.cell.2013.05.039
[2]	Rudnicka E, Napierała P, Podfigurna A, et al. The World Health Organization (WHO) approach to healthy ageing[J]. Maturitas, 2020, 139: 6–11. doi: 10.1016/j.maturitas.2020.05.018
[3]	Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease[J]. Nat Rev Neurol, 2019, 15(10): 565–581. doi: 10.1038/s41582-019-0244-7
[4]	Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases[J]. Expert Rev Mol Med, 2011, 13: e19. doi: 10.1017/S1462399411001918
[5]	Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier[J]. Nat Rev Neurosci, 2006, 7(1): 41–53. doi: 10.1038/nrn1824
[6]	Nutma E, van Gent D, Amor S, et al. Astrocyte and oligodendrocyte cross-talk in the central nervous system[J]. Cells, 2020, 9(3): 600. doi: 10.3390/cells9030600
[7]	Wolf SA, Boddeke HWGM, Kettenmann H. Microglia in physiology and disease[J]. Annu Rev Physiol, 2017, 79: 619–643. doi: 10.1146/annurev-physiol-022516-034406
[8]	Angelova DM, Brown DR. Microglia and the aging brain: are senescent microglia the key to neurodegeneration?[J]. J Neurochem, 2019, 151(6): 676–688. doi: 10.1111/jnc.14860
[9]	Kabba JA, Xu Y, Christian H, et al. Microglia: housekeeper of the central nervous system[J]. Cell Mol Neurobiol, 2018, 38(1): 53–71. doi: 10.1007/s10571-017-0504-2
[10]	Thurgur H, Pinteaux E. Microglia in the neurovascular unit: blood-brain barrier-microglia interactions after central nervous system disorders[J]. Neuroscience, 2019, 405: 55–67. doi: 10.1016/j.neuroscience.2018.06.046
[11]	McTigue DM, Tripathi RB. The life, death, and replacement of oligodendrocytes in the adult CNS[J]. J Neurochem, 2008, 107(1): 1–19. doi: 10.1111/j.1471-4159.2008.05570.x
[12]	Gaudet AD, Fonken LK. Glial cells shape pathology and repair after spinal cord injury[J]. Neurotherapeutics, 2018, 15(3): 554–577. doi: 10.1007/s13311-018-0630-7
[13]	Peferoen L, Kipp M, van der Valk P, et al. Oligodendrocyte-microglia cross-talk in the central nervous system[J]. Immunology, 2014, 141(3): 302–313. doi: 10.1111/imm.12163
[14]	Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease[J]. Pharmacol Rev, 2005, 57(2): 173–185. doi: 10.1124/pr.57.2.4
[15]	Miyazaki I, Asanuma M. Neuron-astrocyte interactions in parkinson's disease[J]. Cells, 2020, 9(12): 2623. doi: 10.3390/cells9122623
[16]	Durkee CA, Araque A. Diversity and specificity of astrocyte-neuron communication[J]. Neuroscience, 2019, 396: 73–78. doi: 10.1016/j.neuroscience.2018.11.010
[17]	Winkler EA, Sagare AP, Zlokovic BV. The pericyte: a forgotten cell type with important implications for Alzheimer's disease?[J]. Brain Pathol, 2014, 24(4): 371–386. doi: 10.1111/bpa.12152
[18]	Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions[J]. Circ Res, 2005, 97(6): 512–523. doi: 10.1161/01.RES.0000182903.16652.d7
[19]	Stebbins MJ, Gastfriend BD, Canfield SG, et al. Human pluripotent stem cell-derived brain pericyte-like cells induce blood-brain barrier properties[J]. Sci Adv, 2019, 5(3): eaau7375. doi: 10.1126/sciadv.aau7375
[20]	Teichert M, Milde L, Holm A, et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation[J]. Nat Commun, 2017, 8: 16106. doi: 10.1038/ncomms16106
[21]	Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis[J]. Nature, 2011, 473(7347): 298–307. doi: 10.1038/nature10144
[22]	Rustenhoven J, Jansson D, Smyth LC, et al. Brain pericytes As mediators of neuroinflammation[J]. Trends Pharmacol Sci, 2017, 38(3): 291–304. doi: 10.1016/j.tips.2016.12.001
[23]	De La Fuente AG, Lange S, Silva ME, et al. Pericytes stimulate oligodendrocyte progenitor cell differentiation during CNS remyelination[J]. Cell Rep, 2017, 20(8): 1755–1764. doi: 10.1016/j.celrep.2017.08.007
[24]	Navarro R, Compte M, Álvarez-Vallina L, et al. Immune regulation by pericytes: modulating innate and adaptive immunity[J]. Front Immunol, 2016, 7: 480. https://pubmed.ncbi.nlm.nih.gov/27867386/
[25]	Smyth LCD, Rustenhoven J, Park TIH, et al. Unique and shared inflammatory profiles of human brain endothelia and pericytes[J]. J Neuroinflammation, 2018, 15(1): 138. doi: 10.1186/s12974-018-1167-8
[26]	Castelli V, Benedetti E, Antonosante A, et al. Neuronal cells rearrangement during aging and neurodegenerative disease: metabolism, oxidative stress and organelles dynamic[J]. Front Mol Neurosci, 2019, 12: 132. doi: 10.3389/fnmol.2019.00132
[27]	Kirch C, Gollo LL. Single-neuron dynamical effects of dendritic pruning implicated in aging and neurodegeneration: towards a measure of neuronal reserve[J]. Sci Rep, 2021, 11(1): 1309. doi: 10.1038/s41598-020-78815-z
[28]	Sandell JH, Peters A. Disrupted myelin and axon loss in the anterior commissure of the aged rhesus monkey[J]. J Comp Neurol, 2003, 466(1): 14–30. doi: 10.1002/cne.10859
[29]	Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment[J]. Drugs Aging, 2001, 18(9): 685–716. doi: 10.2165/00002512-200118090-00004
[30]	Gounder SS, Kannan S, Devadoss D, et al. Impaired transcriptional activity of Nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training[J]. PLoS One, 2012, 7(9): e45697. doi: 10.1371/journal.pone.0045697
[31]	Gu Y, Dee CM, Shen J. Interaction of free radicals, matrix metalloproteinases and caveolin-1 impacts blood-brain barrier permeability[J]. Front Biosci, 2011, 3(4): 1216–1231. https://pubmed.ncbi.nlm.nih.gov/21622267/
[32]	DeBalsi KL, Hoff KE, Copeland WC. Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases[J]. Ageing Res Rev, 2017, 33: 89–104. doi: 10.1016/j.arr.2016.04.006
[33]	Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders[J]. Neuron, 2008, 60(5): 748–766. doi: 10.1016/j.neuron.2008.10.010
[34]	Harris JJ, Jolivet R, Attwell D. Synaptic energy use and supply[J]. Neuron, 2012, 75(5): 762–777. doi: 10.1016/j.neuron.2012.08.019
[35]	Zhuo M, Gorgun MF, Englander EW. Augmentation of glycolytic metabolism by meclizine is indispensable for protection of dorsal root ganglion neurons from hypoxia-induced mitochondrial compromise[J]. Free Radic Biol Med, 2016, 99: 20–31. doi: 10.1016/j.freeradbiomed.2016.07.022
[36]	Takahashi S. Metabolic compartmentalization between astroglia and neurons in physiological and pathophysiological conditions of the neurovascular unit[J]. Neuropathology, 2020, 40(2): 121–137. doi: 10.1111/neup.12639
[37]	Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation[J]. Cell Metab, 2011, 14(6): 724–738. doi: 10.1016/j.cmet.2011.08.016
[38]	Abe T, Takahashi S, Suzuki N. Oxidative metabolism in cultured rat astroglia: effects of reducing the glucose concentration in the culture medium and of D-aspartate or potassium stimulation[J]. J Cereb Blood Flow Metab, 2006, 26(2): 153–160. doi: 10.1038/sj.jcbfm.9600175
[39]	Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization[J]. Proc Natl Acad Sci U S A, 1994, 91(22): 10625–10629. doi: 10.1073/pnas.91.22.10625
[40]	Mergenthaler P, Lindauer U, Dienel GA, et al. Sugar for the brain: the role of glucose in physiological and pathological brain function[J]. Trends Neurosci, 2013, 36(10): 587–597. doi: 10.1016/j.tins.2013.07.001
[41]	Salminen A, Ojala J, Kaarniranta K, et al. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype[J]. Eur J Neurosci, 2011, 34(1): 3–11. doi: 10.1111/j.1460-9568.2011.07738.x
[42]	Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer's disease[J]. PLoS One, 2012, 7(9): e45069. doi: 10.1371/journal.pone.0045069
[43]	Reinert A, Morawski M, Seeger J, et al. Iron concentrations in neurons and glial cells with estimates on ferritin concentrations[J]. BMC Neurosci, 2019, 20(1): 25. doi: 10.1186/s12868-019-0507-7
[44]	Salami A, Papenberg G, Sitnikov R, et al. Elevated neuroinflammation contributes to the deleterious impact of iron overload on brain function in aging[J]. Neuroimage, 2021, 230: 117792. doi: 10.1016/j.neuroimage.2021.117792
[45]	Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease[J]. Cell, 2017, 171(2): 273–285. doi: 10.1016/j.cell.2017.09.021
[46]	Wang J, Song N, Jiang H, et al. Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons[J]. Biochim Biophys Acta Mol Basis Dis, 2013, 1832(5): 618–625. doi: 10.1016/j.bbadis.2013.01.021
[47]	Thomsen MS, Andersen MV, Christoffersen PR, et al. Neurodegeneration with inflammation is accompanied by accumulation of iron and ferritin in microglia and neurons[J]. Neurobiol Dis, 2015, 81: 108–118. doi: 10.1016/j.nbd.2015.03.013
[48]	Damani MR, Zhao L, Fontainhas AM, et al. Age-related alterations in the dynamic behavior of microglia[J]. Aging Cell, 2011, 10(2): 263–276. doi: 10.1111/j.1474-9726.2010.00660.x
[49]	Orre M, Kamphuis W, Osborn LM, et al. Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice[J]. Neurobiol Aging, 2014, 35(1): 1–14. doi: 10.1016/j.neurobiolaging.2013.07.008
[50]	Koellhoffer EC, McCullough LD, Ritzel RM. Old maids: aging and its impact on microglia function[J]. Int J Mol Sci, 2017, 18(4): 769. doi: 10.3390/ijms18040769
[51]	von Bernhardi R, Eugenín-von Bernhardi L, Eugenín J. Microglial cell dysregulation in brain aging and neurodegeneration[J]. Front Aging Neurosci, 2015, 7: 124. doi: 10.3389/fnagi.2015.00124
[52]	Duncombe J, Lennen RJ, Jansen MA, et al. Ageing causes prominent neurovascular dysfunction associated with loss of astrocytic contacts and gliosis[J]. Neuropathol Appl Neurobiol, 2017, 43(6): 477–491. doi: 10.1111/nan.12375
[53]	Mishra A, Reynolds JP, Chen Y, et al. Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles[J]. Nat Neurosci, 2016, 19(12): 1619–1627. doi: 10.1038/nn.4428
[54]	Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging[J]. Neuron, 2010, 68(3): 409–427. doi: 10.1016/j.neuron.2010.09.043
[55]	Lourenço CF, Ledo A, Caetano M, et al. Age-dependent impairment of neurovascular and neurometabolic coupling in the hippocampus[J]. Front Physiol, 2018, 9: 913. doi: 10.3389/fphys.2018.00913
[56]	Balbi M, Ghosh M, Longden TA, et al. Dysfunction of mouse cerebral arteries during early aging[J]. J Cereb Blood Flow Metab, 2015, 35(9): 1445–1453. doi: 10.1038/jcbfm.2015.107
[57]	Fabiani M, Gordon BA, Maclin EL, et al. Neurovascular coupling in normal aging: a combined optical, ERP and fMRI study[J]. Neuroimage, 2014, 85: 592–607. doi: 10.1016/j.neuroimage.2013.04.113
[58]	Graves SI, Baker DJ. Implicating endothelial cell senescence to dysfunction in the ageing and diseased brain[J]. Basic Clin Pharmacol Toxicol, 2020, 127(2): 102–110. doi: 10.1111/bcpt.13403
[59]	Murugesan N, Demarest TG, Madri JA, et al. Brain regional angiogenic potential at the neurovascular unit during normal aging[J]. Neurobiol Aging, 2012, 33(5): 1004.e1–1004.e16. doi: 10.1016/j.neurobiolaging.2011.09.022
[60]	Ungvari Z, Tucsek Z, Sosnowska D, et al. Aging-induced dysregulation of dicer1-dependent microRNA expression impairs angiogenic capacity of rat cerebromicrovascular endothelial cells[J]. J Gerontol A Biol Sci Med Sci, 2013, 68(8): 877–891. doi: 10.1093/gerona/gls242
[61]	Senatorov VV JR, Friedman AR, Milikovsky DZ, et al. Blood-brain barrier dysfunction in aging induces hyperactivation of TGFβ signaling and chronic yet reversible neural dysfunction[J]. Sci Transl Med, 2019, 11(521): eaaw8283. doi: 10.1126/scitranslmed.aaw8283
[62]	Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-β signaling involvement in epileptogenesis[J]. J Neurosci, 2009, 29(28): 8927–8935. doi: 10.1523/JNEUROSCI.0430-09.2009
[63]	Bar-Klein G, Cacheaux LP, Kamintsky L, et al. Losartan prevents acquired epilepsy via TGF-β signaling suppression[J]. Ann Neurol, 2014, 75(6): 864–875. doi: 10.1002/ana.24147
[64]	Levy N, Milikovsky DZ, Baranauskas G, et al. Differential TGF-β signaling in glial subsets underlies IL-6-mediated epileptogenesis in Mice[J]. J Immunol, 2015, 195(4): 1713–1722. doi: 10.4049/jimmunol.1401446
[65]	Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus[J]. Neuron, 2015, 85(2): 296–302. doi: 10.1016/j.neuron.2014.12.032
[66]	Ivens S, Kaufer D, Flores LP, et al. TGF-β receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis[J]. Brain, 2007, 130(2): 535–547. doi: 10.1093/brain/awl317
[67]	Garwood CJ, Ratcliffe LE, Simpson JE, et al. Review: Astrocytes in Alzheimer's disease and other age-associated dementias: a supporting player with a central role[J]. Neuropathol Appl Neurobiol, 2017, 43(4): 281–298. doi: 10.1111/nan.12338
[68]	Simpson JE, Ince PG, Haynes LJ, et al. Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain[J]. Neuropathol Appl Neurobiol, 2010, 36(1): 25–40. doi: 10.1111/j.1365-2990.2009.01030.x
[69]	Angelova DM, Brown DR. Altered processing of β-amyloid in SH-SY5Y cells induced by model senescent microglia[J]. ACS Chem Neurosci, 2018, 9(12): 3137–3152. doi: 10.1021/acschemneuro.8b00334
[70]	Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer's disease mice[J]. J Neurosci, 2008, 28(33): 8354–8360. doi: 10.1523/JNEUROSCI.0616-08.2008
[71]	Yamazaki Y, Kanekiyo T. Blood-brain barrier dysfunction and the pathogenesis of Alzheimer's disease[J]. Int J Mol Sci, 2017, 18(9): 1965. doi: 10.3390/ijms18091965
[72]	Soto-Rojas LO, Pacheco-Herrero M, Martínez-Gómez PA, et al. The neurovascular unit dysfunction in Alzheimer's disease[J]. Int J Mol Sci, 2021, 22(4): 2022. doi: 10.3390/ijms22042022
[73]	Garwood CJ, Simpson JE, Al Mashhadi S, et al. DNA damage response and senescence in endothelial cells of human cerebral cortex and relation to Alzheimer's neuropathology progression: a population-based study in the Medical Research Council Cognitive Function and Ageing Study (MRC-CFAS) cohort[J]. Neuropathol Appl Neurobiol, 2014, 40(7): 802–814. doi: 10.1111/nan.12156
[74]	Procter TV, Williams A, Montagne A. Interplay between brain pericytes and endothelial cells in dementia[J]. Am J Pathol, 2021, 191(11): 1917–1931. doi: 10.1016/j.ajpath.2021.07.003
[75]	Winkler EA, Sengillo JD, Bell RD, et al. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability[J]. J Cereb Blood Flow Metab, 2012, 32(10): 1841–1852. doi: 10.1038/jcbfm.2012.113
[76]	Yang AC, Stevens MY, Chen MB, et al. Physiological blood-brain transport is impaired with age by a shift in transcytosis[J]. Nature, 2020, 583(7816): 425–430. doi: 10.1038/s41586-020-2453-z
[77]	Sengillo JD, Winkler EA, Walker CT, et al. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease[J]. Brain Pathol, 2013, 23(3): 303–310. doi: 10.1111/bpa.12004
[78]	Montagne A, Nikolakopoulou AM, Zhao Z, et al. Pericyte degeneration causes white matter dysfunction in the mouse central nervous system[J]. Nat Med, 2018, 24(3): 326–337. doi: 10.1038/nm.4482
[79]	Rucker HK, Wynder HJ, Thomas WE. Cellular mechanisms of CNS pericytes[J]. Brain Res Bull, 2000, 51(5): 363–369. doi: 10.1016/S0361-9230(99)00260-9
[80]	Barker R, Ashby EL, Wellington D, et al. Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia[J]. Brain, 2014, 137(5): 1524–1532. doi: 10.1093/brain/awu040
[81]	Rajani RM, Quick S, Ruigrok SR, et al. Reversal of endothelial dysfunction reduces white matter vulnerability in cerebral small vessel disease in rats[J]. Sci Transl Med, 2018, 10(448): eaam9507. doi: 10.1126/scitranslmed.aam9507
[82]	Desai BS, Schneider JA, Li J, et al. Evidence of angiogenic vessels in Alzheimer's disease[J]. J Neural Transm (Vienna), 2009, 116(5): 587–597. doi: 10.1007/s00702-009-0226-9
[83]	Gonzalez-Rodriguez P, Zampese E, Surmeier DJ. Selective neuronal vulnerability in Parkinson's disease[J]. Prog Brain Res, 2020, 252: 61–89. https://pubmed.ncbi.nlm.nih.gov/32247375/
[84]	Liang C, Wang TT, Luby-Phelps K, et al. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease[J]. Exp Neurol, 2007, 203(2): 370–380. doi: 10.1016/j.expneurol.2006.08.015
[85]	Fivenson EM, Lautrup S, Sun N, et al. Mitophagy in neurodegeneration and aging[J]. Neurochem Int, 2017, 109: 202–209. doi: 10.1016/j.neuint.2017.02.007
[86]	Gredilla R, Bohr VA, Stevnsner T. Mitochondrial DNA repair and association with aging--an update[J]. Exp Gerontol, 2010, 45(7–8): 478–488. doi: 10.1016/j.exger.2010.01.017
[87]	Youdim MBH, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28[J]. Ann N Y Acad Sci, 2004, 1012: 306–325. doi: 10.1196/annals.1306.025
[88]	Takahashi M, Ko LW, Kulathingal J, et al. Oxidative stress-induced phosphorylation, degradation and aggregation of α-synuclein are linked to upregulated CK2 and cathepsin D[J]. Eur J Neurosci, 2007, 26(4): 863–874. doi: 10.1111/j.1460-9568.2007.05736.x
[89]	Rai SN, Tiwari N, Singh P, et al. Therapeutic potential of vital transcription factors in Alzheimer's and Parkinson's disease with particular emphasis on transcription factor EB mediated autophagy[J]. Front Neurosci, 2021, 15: 777347. doi: 10.3389/fnins.2021.777347
[90]	He J, Zhu G, Wang G, et al. Oxidative stress and neuroinflammation potentiate each other to promote progression of dopamine neurodegeneration[J]. Oxid Med Cell Longev, 2020, 2020: 6137521. doi: 10.1155/2020/6137521
[91]	Rai SN, Singh P, Varshney R, et al. Promising drug targets and associated therapeutic interventions in Parkinson's disease[J]. Neural Regen Res, 2021, 16(9): 1730–1739. doi: 10.4103/1673-5374.306066
[92]	Mbefo MK, Paleologou KE, Boucharaba A, et al. Phosphorylation of synucleins by members of the Polo-like kinase family[J]. J Biol Chem, 2010, 285(4): 2807–2822. doi: 10.1074/jbc.M109.081950
[93]	Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease[J]. Neurobiol Dis, 2018, 109: 249–257. doi: 10.1016/j.nbd.2017.04.004
[94]	Hoenen C, Gustin A, Birck C, et al. Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant[J]. PLoS One, 2016, 11(9): e0162717. doi: 10.1371/journal.pone.0162717
[95]	Zhang Q, Heng Y, Yuan Y, et al. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation[J]. Toxicol Lett, 2017, 265: 30–37. doi: 10.1016/j.toxlet.2016.11.002
[96]	Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson's disease[J]. Neurotherapeutics, 2010, 7(4): 413–423. doi: 10.1016/j.nurt.2010.07.001
[97]	Rodriguez M, Rodriguez-Sabate C, Morales I, et al. Parkinson's disease as a result of aging[J]. Aging Cell, 2015, 14(3): 293–308. doi: 10.1111/acel.12312
[98]	Rai SN, Singh P. Advancement in the modelling and therapeutics of Parkinson's disease[J]. J Chem Neuroanat, 2020, 104: 101752. doi: 10.1016/j.jchemneu.2020.101752
[99]	Martí Y, Matthaeus F, Lau T, et al. Methyl-4-phenylpyridinium (MPP +) differentially affects monoamine release and re-uptake in murine embryonic stem cell-derived dopaminergic and serotonergic neurons[J]. Mol Cell Neurosci, 2017, 83: 37–45. doi: 10.1016/j.mcn.2017.06.009
[100]	Rai SN, Chaturvedi VK, Singh P, et al. Mucuna pruriens in Parkinson's and in some other diseases: recent advancement and future prospective[J]. 3 Biotech, 2020, 10(12): 522. doi: 10.1007/s13205-020-02532-7
[101]	Trovato Salinaro A, Pennisi M, Di Paola R, et al. Neuroinflammation and neurohormesis in the pathogenesis of Alzheimer's disease and Alzheimer-linked pathologies: modulation by nutritional mushrooms[J]. Immun Ageing, 2018, 15: 8. doi: 10.1186/s12979-017-0108-1
[102]	Mancuso C, Pani G, Calabrese V. Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species[J]. Redox Rep, 2006, 11(5): 207–213. doi: 10.1179/135100006X154978
[103]	Calabrese V, Cornelius C, Dinkova-Kostova AT, et al. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders[J]. Antioxid Redox Signal, 2010, 13(11): 1763–1811. doi: 10.1089/ars.2009.3074
[104]	Calabrese V, Mancuso C, Calvani M, et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity[J]. Nat Rev Neurosci, 2007, 8(10): 766–775. doi: 10.1038/nrn2214
[105]	Goodman Y, Mattson MP. Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid β-peptide toxicity[J]. J Neurochem, 1996, 66(2): 869–872. doi: 10.1046/j.1471-4159.1996.66020869.x
[106]	Dirnagl U, Meisel A. Endogenous neuroprotection: mitochondria as gateways to cerebral preconditioning?[J]. Neuropharmacology, 2008, 55(3): 334–344. doi: 10.1016/j.neuropharm.2008.02.017
[107]	Miquel S, Champ C, Day J, et al. Poor cognitive ageing: Vulnerabilities, mechanisms and the impact of nutritional interventions[J]. Ageing Res Rev, 2018, 42: 40–55. doi: 10.1016/j.arr.2017.12.004